Landos Biopharma (LABP) Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced NX-13, the Company’s first-in-class novel, orally administered therapeutic candidate for the treatment of inflammatory bowel disease (IBD), has successfully met all primary and secondary endpoints in a Phase 1 study. The data showed that NX-13 was well tolerated following evaluation of multiple doses over one and seven days compared with placebo.
“The favorable results from this trial underscore the promise of NX-13’s novel multimodal mechanism of action, targeting the NLRX1 pathway locally in the GI tract, and its potential to bring a new approach to treating patients with IBD,” commented Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos. “As a part of our growing franchise of gut-restricted, oral therapeutics for ulcerative colitis (UC) and Crohn’s disease (CD) with novel immunometabolic mechanisms, we are excited that NX-13 met all primary and secondary endpoints in this first-in-humans study.”
“By using Landos’ powerful LANCE discovery and development platform, we have identified three novel mechanisms of therapeutic efficacy (LANCL2, NLRX1 and PLXDC2) and developed seven novel product candidates around those targets. Our lead product candidates (BT-11 and NX-13) are in clinical testing and our development pipeline currently targets up to 14 autoimmune disease indications. We are pleased that it took only 18 months for NX-13 to advance from discovery to Phase 1 clinical testing and we are looking forward to initiating a Phase 1b trial in patients with UC later this year,” commented Raquel Hontecillas, PhD, Chief Scientific Officer of Landos.
The Phase 1 trial was a randomized, double-blind, placebo-controlled single and multiple ascending dose study designed to evaluate the safety, tolerability and pharmacokinetics of NX-13, which was orally administered. The single ascending dose arm consisted of 35 healthy volunteers in a total of five cohorts (250 to 4,000 mg). The multiple ascending dose arm consisted of 21 healthy volunteers enrolled in a total of three cohorts (1,000 to 4,000 mg). Within each cohort in both dose arms, five participants received NX-13 and two participants received placebo. Across the eight cohorts, no SAEs were reported. The maximum tolerated dose was identified to be 10-fold greater than the anticipated therapeutic dose.
Following the positive results from the Phase 1 study, Landos plans to initiate a Phase 1b trial of NX-13 in patients with ulcerative colitis in 2021. Additionally, building on the success of the LANCE computational platform in BT-11 and NX-13, Landos anticipates filing at least three new INDs in 2021.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hartford (HIG) Agrees To Settlement With The Boy Scouts Of America And Pre-announces Estimated First Quarter Prior Year Development And Catastrophe Losses
- Neovasc (NVCN) announced that Tiara Transapical system will be unable to receive European CE mark under current Medical Device Directive regulations